Research programme: microbiome-based therapeutics - Janssen Human Microbiome Institute/Weizmann Institute of Science
Latest Information Update: 10 Feb 2017
At a glance
- Originator Weizmann Institute of Science
- Developer Janssen human microbiome institute; Weizmann Institute of Science
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified